Cancer Treatment Today

It is rare to have myelodysplastic syndrome(MDS) and paroxysmal noctunral hemoglobnuria(PNH) coexist as two full blown disorders but PNH cells can be present in MDS and PNH can resemble some features of MDS. Among acquired stem cell disorders, auch as myelodysplastic syndromes (MDS) and aplastic anaemia (AA), links between paroxysmal nocturnal haemoglobinuria (PNH) and AA, have been often described, whereas the relationship between MDS and PNH

Low platelet counts are a frequent symptom in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Eltrombopag(Promacta) might be a new option to treat this problem in these diseases, provided that it can be shown that it does not stimulate malignant growht. Unfortunately, there is no significant literature to support Promacta in the setting of ongoing treatment for AML with Vidaza or in MDS. Currenlty PROMACTA is not indicated